Publications by authors named "Matthias Ocker"

Claim this Profile
T
Targeted therapy for biliary tract cancer: facts and fictions as well as demands and challenges.
Daniel Neureiter, Peter Ellinghaus, Matthias Ocker

Expert Rev Anticancer Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New frontiers in the pharmacological management of biliary tract carcinomas: the emerging role of drug conjugates.
Matthias Ocker, Christian Mayr, Petra Huber-Cantonati, Tobias Kiesslich, Daniel Neureiter

Expert Opin Pharmacother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The importance of preclinical models for cholangiocarcinoma drug discovery.
Felix J Krendl, Florian Primavesi, Rupert Oberhuber, Daniel Neureiter, Matthias Ocker

Expert Opin Drug Discov· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Matthias Ocker

Nat Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.
Keith Graham, Philip Lienau, Benjamin Bader, Stefan Prechtl, Jan Naujoks, Matthias Ocker

Cell Chem Biol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells.
Dino Bekric, Tobias Kiesslich, Matthias Ocker, Martina Winklmayr, Markus Ritter

PLoS One· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials.
Dominik Kiem, Matthias Ocker, Richard Greil, Daniel Neureiter, Thomas Melchardt

Expert Opin Investig Drugs· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation.
Matthias Ocker, Daniel Neureiter

Expert Opin Investig Drugs· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of acetylshikonin as a novel tubulin polymerization inhibitor with antitumor activity in human hepatocellular carcinoma cells.
Siming Hu, Yongchuan Li, Junqiu Zhou, Kun Xu, Yanqing Pang, Matthias Ocker

J Gastrointest Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions.
Daniel Neureiter, Peter Ellinghaus, Matthias Ocker

Expert Opin Pharmacother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma.
Dino Bekric, Maria Lina Tornesello, Matthias Ocker, Christian Mayr, Tobias Kiesslich

Front Cell Dev Biol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The future is here-targeted therapies are coming of age in biliary tract cancers.
Daniel Neureiter, Matthias Ocker

Chin Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?
Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, Sebastian Stintzing, Matthias Ocker

Cells· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in Abcb4 Mice.
Nora Helmrich, Martin Roderfeld, Anne Baier, Anita Windhorst, Diran Herebian, Matthias Ocker

Cell Mol Gastroenterol Hepatol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation.
Dino Bekric, Matthias Ocker, Christian Mayr, Sebastian Stintzing, Markus Ritter

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
Christian Mayr, Tobias Kiesslich, Dominik Paul Modest, Sebastian Stintzing, Matthias Ocker

Expert Opin Investig Drugs· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future.
Matthias Ocker, Christian Mayr, Tobias Kiesslich, Sebastian Stintzing, Daniel Neureiter

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systems.
Matthias Ocker, Daniel Neureiter

Expert Rev Gastroenterol Hepatol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients.
Ralf Kircheis, Emanuel Haasbach, Daniel Lueftenegger, Willm T Heyken, Matthias Ocker

Front Immunol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting the immune cell landscape in hepatocellular carcinoma-are we understanding complexity?
Matthias Ocker

Ann Transl Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2.
Karuna Irungbam, Yuri Churin, Tomomitsu Matono, Jakob Weglage, Matthias Ocker

Lab Invest· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities in drug development for nonalcoholic steatohepatitis.
Matthias Ocker

Eur J Pharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma.
Matthias Ocker

World J Gastroenterol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Andreas Schneeweiss, Dagmar Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Matthias Ocker

Cancers (Basel)· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications.
Eckhard Klieser, Christian Mayr, Tobias Kiesslich, Till Wissniowski, Pietro Di Fazio, Matthias Ocker

Int J Mol Sci· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis